188 related articles for article (PubMed ID: 31844184)
1. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.
Rushworth LK; Hewit K; Munnings-Tomes S; Somani S; James D; Shanks E; Dufès C; Straube A; Patel R; Leung HY
Br J Cancer; 2020 Feb; 122(4):517-527. PubMed ID: 31844184
[TBL] [Abstract][Full Text] [Related]
2. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
4. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Elayapillai S; Ramraj S; Benbrook DM; Bieniasz M; Wang L; Pathuri G; Isingizwe ZR; Kennedy AL; Zhao YD; Lightfoot S; Hunsucker LA; Gunderson CC
Gynecol Oncol; 2021 Jan; 160(1):302-311. PubMed ID: 33131904
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
[TBL] [Abstract][Full Text] [Related]
6. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
10. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Maia ARR; Linder S; Song JY; Vaarting C; Boon U; Pritchard CEJ; Velds A; Huijbers IJ; van Tellingen O; Jonkers J; Medema RH
Br J Cancer; 2018 Jun; 118(12):1586-1595. PubMed ID: 29736010
[TBL] [Abstract][Full Text] [Related]
11. Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.
Yang Y; Mamouni K; Li X; Chen Y; Kavuri S; Du Y; Fu H; Kucuk O; Wu D
Mol Cancer Ther; 2018 Sep; 17(9):1859-1870. PubMed ID: 29907594
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Cisse O; Quraishi M; Gulluni F; Guffanti F; Mavrommati I; Suthanthirakumaran M; Oh LCR; Schlatter JN; Sarvananthan A; Broggini M; Hirsch E; Falasca M; Maffucci T
J Exp Clin Cancer Res; 2019 Nov; 38(1):472. PubMed ID: 31752944
[TBL] [Abstract][Full Text] [Related]
14. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
[TBL] [Abstract][Full Text] [Related]
15. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
16. Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.
Qu S; Ci X; Xue H; Dong X; Hao J; Lin D; Clermont PL; Wu R; Collins CC; Gout PW; Wang Y
Br J Cancer; 2018 Mar; 118(6):802-812. PubMed ID: 29381682
[TBL] [Abstract][Full Text] [Related]
17. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.
Simbulan-Rosenthal CM; Dakshanamurthy S; Gaur A; Chen YS; Fang HB; Abdussamad M; Zhou H; Zapas J; Calvert V; Petricoin EF; Atkins MB; Byers SW; Rosenthal DS
Oncotarget; 2017 Feb; 8(8):12576-12595. PubMed ID: 28157711
[TBL] [Abstract][Full Text] [Related]
18. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
Wenner CA; Martzen MR; Lu H; Verneris MR; Wang H; Slaton JW
Int J Oncol; 2012 Apr; 40(4):905-13. PubMed ID: 22159900
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
20. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
